Your browser doesn't support javascript.
loading
Seizures in children undergoing stem cell transplantation.
Turón-Viñas, Eulalia; López-Torija, Iván; Coca-Fernández, Elisabet; Badell, Isabel; Sierra-Marcos, Alba; Turón, Marc; Ribosa-Nogué, Roser; Boronat, Susana.
Afiliación
  • Turón-Viñas E; Child Neurology Unit, Pediatrics Service, Hospital Sant Pau, Barcelona, Spain.
  • López-Torija I; Sant Pau Biomedical Research Institute, IIB Sant Pau, Barcelona, Spain.
  • Coca-Fernández E; Pediatric Hematology and Stem Cell Transplant Unit, Pediatrics Service, Hospital Sant Pau, Barcelona, Spain.
  • Badell I; Child Neurology Unit, Pediatrics Service, Hospital Sant Pau, Barcelona, Spain.
  • Sierra-Marcos A; Sant Pau Biomedical Research Institute, IIB Sant Pau, Barcelona, Spain.
  • Turón M; Sant Pau Biomedical Research Institute, IIB Sant Pau, Barcelona, Spain.
  • Ribosa-Nogué R; Pediatric Hematology and Stem Cell Transplant Unit, Pediatrics Service, Hospital Sant Pau, Barcelona, Spain.
  • Boronat S; Sant Pau Biomedical Research Institute, IIB Sant Pau, Barcelona, Spain.
Pediatr Transplant ; 28(1): e14619, 2024 Feb.
Article en En | MEDLINE | ID: mdl-37803946
BACKGROUND: Neurological complications (NCs) are of major concern following hematological stem cell transplantation (HSCT), most of which present with seizures. PROCEDURES: We performed a retrospective study (2002-2018) of patients undergoing HSCT in order to analyze the incidence and aetiologies related to seizures. RESULTS: Of 155 children undergoing HSCT, 27 (17.4%) developed seizures at some point in 2 years of follow-up. The most frequent etiologies were central nervous system (CNS) infection (n = 10), drug toxicity (n = 8), and vascular disease (n = 5). A statistically significant association was found between seizure and the HSCT type (lower risk for a related identical donor, p = .010), prophylactic or therapeutic mycophenolate use (p = .043 and .046, respectively), steroid use (p = .023), selective CD45RA+ depletion (p = .002), pre-engraftment syndrome (p = .007), and chronic graft-versus-host disease (GVHD) severity (p = .030). Seizures predicted evolution to life-threatening complications and admission to intensive care (p < .001) and higher mortality (p = .023). A statistically significant association was also found between seizures and sequelae in survivors (p = .029). Children who developed seizures had a higher risk of CNS infection and vascular disease (odds ratio 37.25 [95% CI: 7.45-186.05] and 12.95 [95% CI 2.24-74.80], respectively). CONCLUSIONS: Neurological complications highly impact survival and outcomes and need to be addressed when facing an HSCT procedure.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Pediatr Transplant Asunto de la revista: PEDIATRIA / TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Vasculares / Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Pediatr Transplant Asunto de la revista: PEDIATRIA / TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Dinamarca